Nasdaq

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...
Nasdaq

Atea Pharmaceuticals Launches Phase 3 C-FORWARD Trial for HCV Treatment Regimen Combining Bemnifosbuvir and Ruzasvir

Atea Pharmaceuticals has announced the initiation of the Phase 3 C-FORWARD trial, which evaluates the combination regimen of bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV). This trial ...

Carroll housing voucher program might change income calculations in 2026

Carroll County residents who use housing choice vouchers could see a change in the way their income is calculated by the end ...

Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Detailed price information for Atea Pharmaceuticals Inc (AVIR-Q) from The Globe and Mail including charting and trades.
Tyler Morning Telegraph

Tyler Neighborhood Services selects 2,000 applicants for Housing Choice Voucher Program

The City of Tyler’s Neighborhood Services Department has selected 2,000 applicants for its Housing Choice Voucher Program following the reopening of the program’s waiting list from June 24 through ...